Combination Therapies Emerge in the Frontline for Renal Cell Carcinoma

Video

Brad McGregor, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses the future of combination therapies in the treatment landscape of renal cell carcinoma. He highlights the positive results from a few combinations that have been tested in clinical trials. 

Brad McGregor, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses the future of combination therapies in the treatment landscape of renal cell carcinoma (RCC). He highlights the positive results from a few combinations that have been tested in clinical trials.

A combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) was found to have response rates of 83% in patients who were previously untreated and over 60% in all patients with RCC in this particular trial, said McGregor.

Related Videos
Martin H. Voss, MD, an expert on kidney cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Martin H. Voss, MD, an expert on kidney cancer
Related Content